A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment.

Trial Profile

A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs AZD 1656 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Dec 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 26 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top